CD274 and metastatic malignant neoplasm: Although PD‐L1 targeted immune checkpoint blockade (ICB) has shown some capability in prolonging survival for patients with metastatic cancer when administered as a monotherapy or in combination with chemotherapy,9 another potential combination partner to anti‐PD‐L1 may include radiotherapy (RT), which may provide additional curative benefits in the clinic.